Avsnitt
-
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?
The evolving payer evidence landscape in the USPreferences for clinical and economic evidence by US payersKey differences between the US and other global markets with regard to evidence, HEOR, and market accessOpportunities and challenges when launching new medicines/medical devices/diagnostics in the USInnovative perspectives on evidence planning and strategy for the US marketUS payers’ perspectives, with exclusive insights from Petauri Evidence’s 2024 US payer survey
In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.
We explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their extensive experience of driving evidence strategies for US pharmaceutical and medical device launches. Additionally, Nicole and Bob share a ‘sneak peek’ of exclusive insights from a recent Petauri US payer insights survey conducted to better understand the evidence landscape from the US payers’ perspective.
They explore:
This episode was first broadcast as a live webinar in October 2024. Learn more at: https://mtechaccess.co.uk/navigating-us-payer-evidence-needs/
Explore more about launching in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?
Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data. Joseph O’Reilly (Principal Medical Statistician, Arcturis) introduces solutions to these challenges using RWD and RWE approaches. Nick Latimer (Analyst, Delta Hat; Professor of Health Economics, University of Sheffield; former NICE Appraisal Committee member) discusses how RWE is assessed by HTA committees. Samantha Gillard (Director – HTA, Mtech Access) facilitates the discussion and puts your questions to our experts
This episode was first broadcast as a live webinar in October 2024. To request a copy of the slides used or to learn more visit: https://mtechaccess.co.uk/rwe-approaches-economic-modelling-hta/
For support with real-world evidence analysis, health economic modelling of health technology assessment, email [email protected] or visit https://mtechaccess.co.uk/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
Saknas det avsnitt?
-
How is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months?
In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon ICS) to explore these challenges.
How ICBs and Directors of Commissioning prepare for winter pressuresThe current key areas of focus at Place and ICB levelSpecific challenges and pressures facing the NHS now and in the run up to winterImmediate and long-term impact of (expected) new government policiesHow industry can best support the NHS as it plans for winter and beyondHow your field teams can engage with NHS commissioners over the next few months
Jo and Karen discuss:This episode was first broadcast as a live webinar in August 2024.
Learn more at https://mtechaccess.co.uk/nhs-winter-planning/
For support with your UK market access and NHS engagement strategy, visit: https://mtechaccess.co.uk/strategic-uk-market-access/ or email [email protected]Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NHS in England? In July 2024, Global Whispers and NHS Whispers came together, to bring you an overarching view of what it takes to access the NHS with a medtech or pharmaceutical innovation.
The key steps for introducing a new health technology to the NHSWho to speak to, when and whereWhat to include in your value proposition to appeal to NHS decision-makers How to best meet key stakeholders’ needsThe challenges of bringing a new technology to the NHS in England
Guest speaker Dr Faris Al-Ramadani who shared his experience of introducing new technologies to the NHS from both sides of the fence: as a PCN Clinical Director and GP Partner, and as a HealthTech and Venture Capital Consultant.
The NHS in England is complex and ever changing. Recent years have seen the introduction of new structures, new decision-makers and new priorities. If you’ve fallen out of the loop of what’s happening with the NHS, this webinar is here to help.
After de-ciphering some of the new(er) NHS terminologies and structures, we discuss:Learn more about this webinar at: https://mtechaccess.co.uk/de-mystifying-the-nhs/
Discover more about how we can support your UK launch strategy at: https://mtechaccess.co.uk/strategic-uk-market-access/
This webinar was first broadcast live as a webinar in July 2024Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–25?
In this webinar, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) spoke to a panel of NHS Associates about the current state and future of primary care and what this means for industry. Our panellists were:
- Jack Wagstaff (Place Leader, Surrey Heartlands Health and Care Partnership, Chief Officer for North West Surrey Health and Care Alliance)
- Zafran Azam (Head of Medicines Optimisation and Delivery, Derby City Place)
- Dr Neil Forster (GP and PCN Clinical Director, Northumberland Medical Alliance)
We explore:
- Where NHS primary care is heading and what this means for your strategy and business planning
- Prescribing and decision-making in primary care
- The implications of the GP Contract for PCNs, GPs, patients, and industry
- What this means for integration and the integrated care model
- Policy priorities in practice and what to expect in an election year
- How Pharma, Medtech, and Diagnostics companies can best engage with primary care leaders
Learn more at: https://mtechaccess.co.uk/nhs-primary-care-gp-contract/
Discover more about our UK market access services at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
Discover how data visualisation dashboards can aid field teams in market access discussions with customers.
Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a well-designed, easy-to-use visualisation can build a case for change, while positioning themselves as a trusted partner. Watch this 20-minute discussion between Iain Shield (Associate Director – Market Access) and Ben Spurr (Head of Partnerships) to discover how Connected Insights data visualisation dashboards can help your teams have strategic conversations with healthcare decision-makers. Iain also explains typical use cases for the dashboards for field teams, why data dashboards are useful for the NHS, and what sets Connected Insights dashboards apart.
Learn more about this showcase at: https://mtechaccess.co.uk/engage-nhs-with-rwd/
Learn more about real-world data visualisation at: https://mtechaccess.co.uk/digital-capabilities/real-world-data-market-access/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ottawa).
The market access landscape in CanadaUpcoming changes at CADTHWhat Canadian payers expect from your value propositionOpportunities and challenges when launching new medicines/medical devices/diagnostics in CanadaHow Canada compares to the USA/key European launch marketsWhat this means for your global market access strategy
We take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Husereau explore:This episode was first broadcast as a live webinar in March 2024. Learn more at https://mtechaccess.co.uk/market-access-canada-changes-cadth/
Learn more about the Canadian healthcare market and launching new pharma and medtech innovations at: https://mtechaccess.co.uk/launching-healthcare-products-in-canada/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?
In this webinar, our Global Market Access team compare and contrast access opportunities and challenges for rare disease treatments in the differing markets of the Nordic and MENA regions, asking: what does this mean for your overarching market access strategy?
Our Global Market Access experts explore contrasting regions to showcase the significant differences between international markets when it comes to:
- Overall and rare disease patient populations
- Access inequalities
- Time to diagnosis
- Access to innovation timelines
- Healthcare funding
- Health technology assessment frameworks
Robert Taaffe (Consultant – Global Market Access) presents his research into the market access conditions in the MENA regions, with a focus on the rare disease reimbursement landscape in growth markets in Egypt, Saudi Arabia, and the United Arab Emirates.
Michelle James (Associate Consultant – Global Market Access) showcases market access and reimbursement routes in the more established, yet smaller populations in the Nordic regions. Michelle will focus on access in Denmark, Sweden, and Norway.
Clare Foy (Director – Global Market Access) leads our discussion on the opportunities and challenges of launching in markets with different conditions and requirements, and how this should play into your overarching Global market access strategy.
Learn more at and request a copy of the webinar slides at: https://mtechaccess.co.uk/rare-disease-market-access-nordic-and-mena/
Discover how Mtech Access can support you with market access, pricing and reimbursement for rare disease treatments at: https://mtechaccess.co.uk/global-market-access-and-pricing/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
Which decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders?
We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion that explored finance, funding flows, system priorities, and the decision-making process in NHS Regions.
Richard heads up system co-ordination work across the NHS South West Region. The Region has seven Integrated Care Boards (ICBs), 22 Trusts, nine counties and a resident population of over 5.5 million patients stretching from Gloucestershire and Wiltshire to the Isles of Scilly.
The interview was led by David Thorne (Principal Consultant, Mtech Access and Transformation Director at Well Up North Primary Care Network [PCN]) who put both the NHS and industry perspectives to Richard to explore the real state of the NHS.
In this episode, David and Richard discuss:
- Where the NHS is heading and what this means for your strategy and business planning
- Decision making, finances, and funding flows across the NHS
- The role of NHS Regions, particularly with key funding decisions like Specialised Commissioning
- Delivering service change across integrated systems
- Policy priorities in practice and what to expect in an election year
- How Pharma, Medtech, and Diagnostics companies can best engage NHS leaders at Region level
This episode was first broadcast as a live webinar in February 2024.
Learn more about the webinar and Richard at: https://mtechaccess.co.uk/how-does-funding-flow-in-nhse-regions/
Discover more about our NHS Insights services at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation?
Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by guest speakers Debbie Morgan (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Foundation Trust), Ellen Rule (Deputy CEO/Director of Strategy & Transformation, Gloucestershire Integrated Care Board) and Dr Viren Mehta (GP Partner, GP Federation Chief Officer, Viaduct Care). Together we explored what all this uncertainty means for NHS decision-making, day-to-day operations, strategy, and engagement with industry.
In this webinar, we bring together leaders from across the NHS to explore how they are planning and operating in this uncertainty.
We explore:
- Strategy and planning in these times of uncertainty
- What’s happening with GP contracts
- Financial pressures and challenges
- If/where it’s possible to drive forward change in the current environment
- How Pharma and Medtech can best support NHS leaders
- Where the panel would welcome solutions from industry
Please note this episode was first broadcast in January 2024 as a live webinar. Some aspects of policy discussed have evolved and continue to evolve.
Discover more at: https://mtechaccess.co.uk/nhs-policy-for-2024-25/
Learn more about our NHS insights services at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
What is health economic evaluation and which modelling approaches can be used to support market access activities?
In this episode, our expert health economists explain the key strengths and limitations of the most common health economic modelling classifications and structures. Here, Hannah Gillies (Consultant – Health Economics) and Daniel MacDonald (Associate Consultant – Health Economics) de-mystify the different approaches to health economic modelling.
Our specialists explore six of the most common health economic modelling structures used to support market access activities;
- Decision trees
- Markov models
- Semi-Markov models
- Partitioned survival models
- Cox regression models
- Discrete event simulations
This episode was first broadcast as a live webinar in January 2024. For more information or to request a copy of the slides used, please visit: https://mtechaccess.co.uk/de-mystifying-health-economic-models/
Work with our health economists: https://mtechaccess.co.uk/health-economics/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
Here, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies.
Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be appropriate for your product? What will payers, HTA agencies, and other key decision makers be looking for? And how should this information be presented?
In this episode, our experts in HTA, health economics, and commercialisation explore:
- How to identify and communicate the value of your product for patients and the wider healthcare system
- How to build a robust evidence package for successful launch and commercialisation
- Key requirements for the National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programme (MTEP) or Diagnostics Assessment Programme (DAP)
- Next steps to take your innovation to healthcare leaders across the NHS and beyond, with an impactful customer communication strategy
This episode was first broadcast as a live webinar in January 2023. Learn more and request a copy of the slides at: https://mtechaccess.co.uk/evidence-strategy-for-medical-technologies-and-diagnostics/
Discover how Mtech Access can support your commercialisation journey at: https://mtechaccess.co.uk/medical-device-market-access/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
How can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launching in the US market.
Clare Foy (Director – Global Market Access, Mtech Access) speaks to Janice MacLennan (Pharma and Medtech brand strategist and founder of NMBLR) about how market access, HEOR and commercialisation leads in Pharma and Medtech can best support overarching product and brand strategy, with a focus on launch challenges in the US market.
We take a step back from the intricacies of market access and HEOR, to explore the role our specialism plays in broader commercial and product strategy. We ask: where does market access and HEOR sit in this broader picture, and how can market access teams best support their product and company brand?
Using the US market as our case study, we explore:
- How to set up your product for success
- Commercialisation routes in the US for Pharma and Medtech
- The relationship between brand strategy and market access
- What Pharma can learn from Medtech’s approach to commercialisation
- What Medtech innovators can learn from Pharma companies’ approach to launch
This episode was first broadcast as a live webinar in January 2024.
Learn more at: https://mtechaccess.co.uk/commercialisation-strategy-us-market/
Explore our work in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/
Discover how Mtech Access can support you global market access and pricing strategy: https://mtechaccess.co.uk/global-market-access-and-pricing/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?
Specialised commissioning in the NHSThe risks and opportunities that devolution to ICBs will bringWhat we can expect to see in the short and longer termHow industry can support ICB leaders through this transitionHow Pharma, Medtech, and Diagnostics companies, whose products come under specialised commissioning, can manage these risks and uncertainties
Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to explore specialised commissioning in the NHS and what to expect as we head into 2024.
Malcolm Qualie and David Thorne explored:
Learn more at https://mtechaccess.co.uk/nhs-specialised-commissioning/
This episode first broadcast as a live webinar in Decmeber 2023.Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
What does it take to run a truly patient-centric integrated health system? What does the Welsh journey with integration tell us about the future for England?
Paul Mears (CEO, Cwm Taf Morgannwg University Health Board) joins Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) to explore the integrated care model in Wales and the lessons England can take from the Welsh experience.
In this NHS Whispers webinar, guest speaker Paul Mears shares his experiences leading a Welsh health board. The 7 Health Boards in Wales have been operating as integrated systems for over a decade. With the NHS in England just getting to grips with integration, we explore what England can learn from the Welsh experience.
Robert and Paul explore:
- How NHS Wales is structured and who the key decision makers are
- How the integrated healthcare system works in Wales and how this differs to what’s happening in England
- How priorities are set and what shapes decision-making at health board level
- The nuances of the Welsh health system and what this means for industry
- How Welsh Health Boards work with industry and the lessons here for ICBs and industry in England
- Prudent healthcare and what this means in practice
- How industry can best engage with health board leaders, what channels to use, and what messages to bring
This episode was first broadcast live as webinar in November 2023
Learn more about this webinar at: https://mtechaccess.co.uk/integrated-care-in-nhs-wales/
Discover how we can help you with your NHS engagement and UK market access strategy at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
Clare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, particularly regarding changes at the Agenzia Italiana del Farmaco (AIFA).
We explore:
- The nature of the Italian market and the reimbursement process
- Pricing and market access considerations when launching in Italy
- What the reforms at AIFA mean for market access and managed entry agreements
- How the AIFA changes specifically impact innovative products
- Changes to early access programmes in Italy
- Impact of these changes on international pricing, particularly with the introduction of the EU Joint Clinical Assessment (JCA)
This episode was first broadcast as a live webinar in October 2023. Learn more at: https://mtechaccess.co.uk/italy-market-access-aifa-reforms/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
Dr Farzana Hussain (GP Principal, The Project Surgery) and Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) explore the unmet needs of Primary Care Networks (PCNs) and how industry can best support primary care leaders and GPs as we head into winter, 2024 and beyond.
How unmet needs are identified in primary care, the processes followed, and datasets used to inform decision making The specific challenges facing primary care as we head into winter The role of PCN leaders and their impact on national policy How industry can best support and collaborate with PCNs Ongoing lessons from the pandemic and the vaccine roll-out
Former ‘GP of the year’ and strategic influencer over primary care policy, Dr Farzana Hussain, discusses the unmet needs in primary care, how primary care leaders are responding to these challenges, and where industry can best offer support.
Phil and Farzana discuss:
Learn more about this webinar at: https://mtechaccess.co.uk/unmet-need-nhs-primary-care/
Discover or NHS Insight and UK market access services: https://mtechaccess.co.uk/uk-nhs-insights/
This episode was first broadcast as a live webinar in October 2023.Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
How can our community support NHS leaders to deliver a data-led, people-centric health service?
Dr Mark Davies (Global Chief Health Officer, IBM) joins Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) to explore the power of data, the role of community and how the health and life sciences ecosystem can support the NHS’s population health management goals.
Population health management has the potential to be a powerful tool for healthcare systems, effecting the way health and care is strategised, budgeted, targeted, and delivered. We see a future where key decisions in the NHS are driven by population health data. What we now need is a new way of working powered by local need, quality evidence and a systematic approach.
In this webinar, Phil and Mark explore:
- How the NHS can use population health management to transform the system
- The importance of community in population health management
- How Pharma, Medtech, and the wider life sciences sector can work above brand to support the NHS with population health management
- What a data-driven, people-centric approach means for the way treatments are valued
- How population health management could transform the economics of healthcare
This episode was first broadcast as a live webinar on Friday 8th September 2023. Learn more at: https://mtechaccess.co.uk/uk-nhs-insights/
Discover more about our work in this area at: https://mtechaccess.co.uk/uk-nhs-insights/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
How is Artificial Intelligence being used in the development of new medicines? What role can AI currently play in clinical trials? Where can AI bridge gaps and solve challenges? What could this mean for the future of market access?
In this webinar, Dr George Magrath explains how his team at Lexitas are using AI in clinical trials in the field of ophthalmology. George and Calum explore:
- How, when and where AI is being used in clinical trials
- How Lexitas are using AI in clinical trials for ophthalmology
- Where AI may offer solutions to existing obstacles in clinical trials and ophthalmic drug development
- What the future holds for AI in the development of new medicines
- The role AI can play in selecting patients for clinical trials
- The impact AI may have on the way we evaluate drug effectiveness
- What this all means for evidence synthesis, health economics, reimbursement and market access
- The future prospects of AI in pharmaceutical development
Learn more at: https://mtechaccess.co.uk/ai-clinical-trials-evidence/
This episode was first broadcast as a live webinar in August 2023.Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
-
How is the UK political landscape evolving and what does this mean for Health Technology and Medical Device innovators?
MHRA and new medical device regulatory regimeUK health and social care supply and procurementSustainability and social valueAddressing capacity challenges with effective health and social care packagesInnovationExport and import – the implications of Brexit
Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) speaks to William Lee (Head of Policy and Compliance, British Healthcare Trades Association [BHTA]) about health policy, regulation and its implications for Medtech, Health technologies, and Medical Device market access.
With the challenges of the pandemic and the changes brought in following Brexit, policy and compliance in the UK has been on shifting sands for several years now. With many predicting a change in government at the next election, this continues to be a time of uncertainty. What does this political landscape mean for health policy, the regulatory regime and market access?
In this on-demand webinar, Rob asks Bill about 6 areas where Medtech should be paying attention:
This episode was first broadcast as a live webinar in July 2023. Learn more about this webinar at: https://mtechaccess.co.uk/uk-health-policy-medtech-bhta-webinar/
Learn more about our services for Medtech companies at: https://mtechaccess.co.uk/medical-device-market-access/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
- Visa fler
